Rallybio Corporation – Filings and Transcripts

NASDAQ: RLYB
Share price (6/1/26): $16.87
Market cap (6/1/26): $89.4 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

Prospectuses and Registrations Filter

Business combination disclosure

Registration withdrawal request

Details of business combination or exchange offer – amended

Details of business combination or exchange offer

Business combination disclosure

Ownership Filter

Schneeberger Daniel, ADAR1 Capital Management, LLC

Balyasny Asset Management L.P.

Cormorant Asset Management, LP

Schneeberger Daniel, ADAR1 Capital Management, LLC

Nantahala Capital Management, LLC

News Filter

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

Termination of Material Definitive Agreement, Financial Statements or Exhibits

Change in Directors, Officers or Compensation

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Shareholder Vote Results, Financial Statements or Exhibits

Proxies Filter

Definitive proxy

Preliminary proxy

Definitive proxy

Definitive proxy

Definitive proxy

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness

Correspondence with the SEC